Basic information
Biomarker: LDH-5
Histology type: endometrial carcinoma
Cohort characteristics
Country: Greece
Region: Alexandroupolis
Followed up time :
Subgroup 1 name : Low
Subgroup 1 number: 37
Subgroup 2 name: High
Subgroup 2 number: 31
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 88 | stage I endometrial adenocarcinoma | 68 | normally cycling endometrium | 20 |
Sample information
Conclusion: LDH-5 expression is an independent prognostic marker in endometrial cancer, linked with impaired host immune response and activation of VEGFR2/KDR receptors in both cancer cells and tumor-associated vasculature. Adjuvant radio-chemotherapy may, therefore, be useful in these cases, while the administration of VEGF- tyrosine kinase receptor inhibitors emerges as a therapeutic option.
Sample type : tissue
Sample method: immunohistochemistry
Expression pattern : high expression
Expression elevation: Strong cytoplasmic reactivity in more than 50% of cancer cells and/or nuclear expression in more than 10% of cancer cells was scored as ‘high’ expression, while all other cases (including weak cytoplasmic or strong cytoplasmic in <50% of cells) were scored as ‘low’.
Disease information
Related information
UniProt Link:
Molecular function from UniProt:
